242 related articles for article (PubMed ID: 26009281)
21. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
22. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
Na HY; Choe JY; Shin SA; Kim HJ; Han JH; Kim HK; Oh SH; Kim JE
PLoS One; 2019; 14(10):e0224247. PubMed ID: 31644584
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiling of diffuse large B-cell lymphoma supervised by CD21 expression.
Miyazaki K; Yamaguchi M; Suguro M; Choi W; Ji Y; Xiao L; Zhang W; Ogawa S; Katayama N; Shiku H; Kobayashi T
Br J Haematol; 2008 Aug; 142(4):562-70. PubMed ID: 18537973
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas.
Zheng J; Xu J; Ma S; Sun X; Geng M; Wang L
Int J Clin Exp Pathol; 2013; 6(10):2048-55. PubMed ID: 24133582
[TBL] [Abstract][Full Text] [Related]
27. Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival.
Yoshioka T; Miura I; Kume M; Takahashi N; Okamoto M; Ichinohasama R; Yoshino T; Yamaguchi M; Hirokawa M; Sawada K; Nakamura S
Genes Chromosomes Cancer; 2005 Feb; 42(2):149-57. PubMed ID: 15543600
[TBL] [Abstract][Full Text] [Related]
28. Identification of CD5/Cyclin D1 Double-negative Pleomorphic Mantle Cell Lymphoma: A Clinicopathologic, Genetic, and Gene Expression Study.
Chuang WY; Chang ST; Yuan CT; Chang GJ; Chang H; Yeh CJ; Ueng SH; Kao HW; Wang TH; Wan YL; Shih LY; Chuang SS; Hsueh C
Am J Surg Pathol; 2020 Feb; 44(2):232-240. PubMed ID: 31688139
[TBL] [Abstract][Full Text] [Related]
29. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature.
Suguro M; Tagawa H; Kagami Y; Okamoto M; Ohshima K; Shiku H; Morishima Y; Nakamura S; Seto M
Cancer Sci; 2006 Sep; 97(9):868-74. PubMed ID: 16856881
[TBL] [Abstract][Full Text] [Related]
30. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center.
Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH
Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403
[TBL] [Abstract][Full Text] [Related]
31. De novo CD5 positive diffuse large B-cell lymphomas with bone marrow involvement in Korean.
Kong SY; Cho EH; Woo HY; Park Q; Ko YH; Kim SH
J Korean Med Sci; 2004 Dec; 19(6):815-9. PubMed ID: 15608391
[TBL] [Abstract][Full Text] [Related]
32. De Novo CD5
Xu Y; Sun W; Li F
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e782-e790. PubMed ID: 32694049
[TBL] [Abstract][Full Text] [Related]
33. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
Davis RE; Brown KD; Siebenlist U; Staudt LM
J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
[TBL] [Abstract][Full Text] [Related]
34. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis.
Scholtysik R; Kreuz M; Hummel M; Rosolowski M; Szczepanowski M; Klapper W; Loeffler M; Trümper L; Siebert R; Küppers R;
Int J Cancer; 2015 Mar; 136(5):1033-42. PubMed ID: 25042405
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
[TBL] [Abstract][Full Text] [Related]
36. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
[TBL] [Abstract][Full Text] [Related]
37. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
38. An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL.
Mai Y; Yu JJ; Bartholdy B; Xu-Monette ZY; Knapp EE; Yuan F; Chen H; Ding BB; Yao Z; Das B; Zou Y; Young KH; Parekh S; Ye BH
Blood; 2016 Dec; 128(24):2797-2807. PubMed ID: 27737889
[TBL] [Abstract][Full Text] [Related]
39. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.
Shaknovich R; Geng H; Johnson NA; Tsikitas L; Cerchietti L; Greally JM; Gascoyne RD; Elemento O; Melnick A
Blood; 2010 Nov; 116(20):e81-9. PubMed ID: 20610814
[TBL] [Abstract][Full Text] [Related]
40. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.
Wright G; Tan B; Rosenwald A; Hurt EH; Wiestner A; Staudt LM
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9991-6. PubMed ID: 12900505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
